Last reviewed · How we verify

Short-Term Varenicline — Competitive Intelligence Brief

Short-Term Varenicline (short-term-varenicline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg t. Area: Other.

preclinical varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg t Other Live · refreshed every 30 min

Target snapshot

Short-Term Varenicline (short-term-varenicline) — Pfizer Inc.. varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg t

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Short-Term Varenicline TARGET short-term-varenicline Pfizer Inc. preclinical varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg t

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg t class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Short-Term Varenicline — Competitive Intelligence Brief. https://druglandscape.com/ci/short-term-varenicline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing